Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9920568 | 0.85 | MAPT (0.33) | ALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL9920547 | 0.78 | ESR2 (0.50) | ALDH1A1HPGDMAPK1MAPK10MEN1 | |
| SCHEMBL9920554 | 0.78 | MAPK9 (0.47) | KDRMAPK10MAPK9 | |
| SCHEMBL9920566 | 0.75 | KDM4E (0.41) | — | |
| SCHEMBL9920525 | 0.75 | KDM4E (0.41) | — | |
| SCHEMBL822814 | 0.75 | ALDH1A1 (0.53) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL12879656 | 0.75 | KDM4E (0.38) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL12219219 | 0.75 | KDM4E (0.38) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL9920567 | 0.74 | IL1R1 (0.34) | ALDH1A1MEN1KMT2A | |
| SCHEMBL9920569 | 0.73 | ACHE (0.34) | ALDH1A1LMNAHPGDSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458182-B2 | Silyl- and heteroatom-substituted compounds selected from carbazoles, dibenzofurans, dibenzothiophenes and dibenzophospholes, and use thereof in organic electronics | BASF SE (DE) | 2016-10-04 | — | — | US | disclosed |
| US-8691401-B2 | Bridged benzimidazole-carbene complexes and use thereof in OLEDS | BASF SE (DE) | 2014-04-08 | — | — | US | disclosed |
| US-20120012821-A1 | SILYL- AND HETEROATOM-SUBSTITUTED COMPOUNDS SELECTED FROM CARBAZOLES, DIBENZOFURANS, DIBENZOTHIOPHENES AND DIBENZOPHOSPHOLES, AND USE THEREOF IN ORGANIC ELECTRONICS | BASF SE (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20110253988-A1 | BRIDGED BENZIMIDAZOLE-CARBENE COMPLEXES AND USE THEREOF IN OLEDS | BASF SE (DE) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110253988-A1 | BRIDGED BENZIMIDAZOLE-CARBENE COMPLEXES AND USE THEREOF IN OLEDS | CCND1, DRD2, CCND2 | HPGDS 2305/4885ALDH1A1 502/4885LMNA 4493/4885 |
| US-20120012821-A1 | SILYL- AND HETEROATOM-SUBSTITUTED COMPOUNDS SELECTED FROM CARBAZOLES, DIBENZOFURANS, DIBENZOTHIOPHENES AND DIBENZOPHOSPHOLES, AND USE THEREOF IN ORGANIC ELECTRONICS | DDT, CDKL1, CDK2 | HPGDS 3469/4885ALDH1A1 750/4885LMNA 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.